Category: Pharmaceuticals and Biotech

Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma
Press Release Jan 2, 2018
Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma

Broadens immunomodulatory peptide portfolio while also expanding route of administration capabilities

Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis
Press Release Oct 27, 2017
Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis

Launches preclinical development effort of LBT-3627 as a neuroprotective/repair treatment for Multiple Sclerosis

Press Release Oct 11, 2017
Longevity Biotech Granted US Patent Covering Hybridtide Platform Technology for Stabilized Peptide Therapeutics
Longevity Biotech and University of Nebraska Medical Center Awarded Continuing Grant from the Michael J. Fox Foundation for Parkinson's Research
Press Release Feb 7, 2017
Longevity Biotech and University of Nebraska Medical Center Awarded Continuing Grant from the Michael J. Fox Foundation for Parkinson's Research

Furthers development of LBT-3627 focusing on immunomodulatory therapeutic strategy to treat Parkinson's disease
Pioneering Neuroprotective Results Achieved in Parkinson's Disease Preclinical Studies
Press Release Dec 16, 2015
Pioneering Neuroprotective Results Achieved in Parkinson's Disease Preclinical Studies

Allows immune system to repair brain damage; results reported in Journal of Neuroscience